DK2187882T3 - Behandling af progressiv neurodegenerativ sygdom med ibudilast - Google Patents
Behandling af progressiv neurodegenerativ sygdom med ibudilastInfo
- Publication number
- DK2187882T3 DK2187882T3 DK08781498.4T DK08781498T DK2187882T3 DK 2187882 T3 DK2187882 T3 DK 2187882T3 DK 08781498 T DK08781498 T DK 08781498T DK 2187882 T3 DK2187882 T3 DK 2187882T3
- Authority
- DK
- Denmark
- Prior art keywords
- ibudilast
- treatment
- neurodegenerative disease
- progressive neurodegenerative
- progressive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92974507P | 2007-07-11 | 2007-07-11 | |
| US4218108P | 2008-04-03 | 2008-04-03 | |
| PCT/US2008/069417 WO2009009529A1 (en) | 2007-07-11 | 2008-07-08 | Treatment of progressive neurodegenerative disease with ibudilast |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2187882T3 true DK2187882T3 (da) | 2013-04-08 |
Family
ID=39789775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08781498.4T DK2187882T3 (da) | 2007-07-11 | 2008-07-08 | Behandling af progressiv neurodegenerativ sygdom med ibudilast |
Country Status (14)
| Country | Link |
|---|---|
| US (9) | US8138201B2 (da) |
| EP (2) | EP2567699A1 (da) |
| JP (2) | JP5468001B2 (da) |
| CN (1) | CN101848712B (da) |
| AU (1) | AU2008275148A1 (da) |
| BR (1) | BRPI0814624A2 (da) |
| CA (2) | CA2970273C (da) |
| DK (1) | DK2187882T3 (da) |
| ES (1) | ES2402175T3 (da) |
| HR (1) | HRP20130057T1 (da) |
| PL (1) | PL2187882T3 (da) |
| PT (1) | PT2187882E (da) |
| TW (1) | TW200918051A (da) |
| WO (1) | WO2009009529A1 (da) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ597378A (en) * | 2009-06-19 | 2014-08-29 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
| BRPI1011939A2 (pt) * | 2009-06-23 | 2016-04-26 | Medicinova Inc | composições enantioméricas de 2-amino-1-(2-isopropilpirazolo[1,5-a]piridin-3-il) propano-1-ona e métodos relacionados. |
| ES2564931T3 (es) * | 2009-07-30 | 2016-03-30 | Teva Pharmaceutical Industries Ltd. | Tratamiento de enfermedad de Crohn con laquinimod |
| DK2467372T3 (da) * | 2009-08-10 | 2016-08-22 | Teva Pharma | Behandling af bdnf-relaterede lidelser under anvendelse af laquinimod |
| EP2398488B1 (en) * | 2010-01-04 | 2018-11-14 | Mapi Pharma Limited | Depot system comprising glatiramer acetate |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| PT2542079E (pt) * | 2010-03-03 | 2014-07-18 | Teva Pharma | Tratamento da artrite reumatoide com uma combinação de laquinimod e metotrexato |
| PE20130613A1 (es) * | 2010-03-03 | 2013-06-23 | Teva Pharma | Tratamiento de lupus nefritis usando laquinimod |
| SG183515A1 (en) * | 2010-03-03 | 2012-10-30 | Teva Pharma | Treatment of lupus arthritis using laquinimod |
| EP2699317B1 (en) | 2011-04-21 | 2016-08-10 | Mapi Pharma Limited | Random pentapolymer for treatment of autoimmune diseases |
| US8889627B2 (en) | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| WO2013116657A1 (en) | 2012-02-03 | 2013-08-08 | Teva Pharmaceutical Industries Ltd. | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
| CN103255142B (zh) * | 2012-02-21 | 2017-07-25 | 上海转基因研究中心 | 一种利用RNAi调控内源性朊蛋白表达的方法及其应用 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| CN103505731A (zh) * | 2012-06-15 | 2014-01-15 | 中国药科大学 | 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途 |
| FR3000746A1 (fr) | 2013-01-04 | 2014-07-11 | Centre Nat Rech Scient | Peptide pour son utilisation dans le traitement des neuronopathies motrices |
| AU2014216199A1 (en) * | 2013-02-15 | 2015-09-03 | Teva Pharmaceutical Industries Ltd. | Treatment of progressive forms of multiple sclerosis with laquinimod |
| JP2016517883A (ja) * | 2013-05-03 | 2016-06-20 | オレゴン ヘルス アンド サイエンス ユニバーシティー | Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 |
| AU2015253330A1 (en) | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
| US20150366847A1 (en) * | 2014-06-20 | 2015-12-24 | Medicinova, Inc. | Combination of geranylgeranylacetone and ibudilast and methods of using same |
| EP3193870A4 (en) * | 2014-09-16 | 2018-04-25 | Teva Pharmaceutical Industries Ltd. | Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod |
| JP6827924B2 (ja) | 2014-11-26 | 2021-02-10 | メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． | イブジラスト及びリルゾールの組み合わせを含む医薬および組成物 |
| WO2016086000A1 (en) * | 2014-11-26 | 2016-06-02 | Medicinova, Inc. | A combination of geranygeranylacetone, ibudilast, and riluzole and methods of using same |
| CN105395511A (zh) * | 2015-12-07 | 2016-03-16 | 黑龙江省智诚医药科技有限公司 | 一种异丁司特缓释微丸及其制备方法 |
| EP3454853B1 (en) * | 2016-05-10 | 2022-05-18 | MediciNova, Inc. | Treatment of alcoholism and depression using ibudilast |
| JP2020504721A (ja) | 2016-12-22 | 2020-02-13 | メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． | イブジラストを使用した多形膠芽腫の治療方法 |
| CA3050086A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| WO2019157428A1 (en) * | 2018-02-12 | 2019-08-15 | Medicinova, Inc. | Methods of suppressing myeloid-derived suppressor cells in patients |
| US10744123B2 (en) | 2018-02-12 | 2020-08-18 | Medicinova, Inc. | Methods and dosing regimens using ibudilast and a second agent for cancer therapy |
| EP3863628B1 (en) * | 2018-10-09 | 2023-12-27 | MediciNova, Inc. | Combination of ibudilast and interferon-beta and methods of using same |
| CA3116577A1 (en) * | 2018-10-19 | 2020-04-23 | Medicinova, Inc. | Methods of treating ophthalmic disease/disorder or injury with ibudilast |
| EP3894383A1 (en) | 2018-12-12 | 2021-10-20 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
| JP2022524930A (ja) * | 2019-02-26 | 2022-05-11 | ウニベルシタット デ バレンシア―エストゥディ ジェネラル | 運動ニューロン疾患を処置するための方法及び組成物 |
| US11667606B2 (en) | 2019-03-01 | 2023-06-06 | Autobahn Therapeutics, Inc. | Thyromimetics |
| US20220347159A1 (en) * | 2019-06-11 | 2022-11-03 | Yale University | Novel treatment for wolfram syndrome |
| EP4034090A1 (en) | 2019-09-23 | 2022-08-03 | MediciNova, Inc. | Ibudilast oral formulations and methods of using same |
| EP4132521A1 (en) * | 2020-04-06 | 2023-02-15 | MediciNova, Inc. | Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast |
| US11925625B2 (en) | 2021-01-29 | 2024-03-12 | Medicinova, Inc. | Methods of treating chemical gas exposure |
| WO2023009425A1 (en) | 2021-07-26 | 2023-02-02 | Medicinova, Inc. | Ibudilast for preventing eye cancer metastasis |
| US20230090534A1 (en) | 2021-09-21 | 2023-03-23 | Medicinova, Inc. | Methods of treating glioblastoma multiforme using combination therapy |
| WO2023150093A1 (en) | 2022-02-01 | 2023-08-10 | Medicinova, Inc. | Ibudilast for use in the treatment of post-covid conditions |
| WO2023192885A2 (en) * | 2022-03-28 | 2023-10-05 | Praxis Precision Medicines, Inc. | Methods of using oligomeric compounds to treat scn2a-related disorders |
| WO2024015415A1 (en) | 2022-07-13 | 2024-01-18 | Medicinova, Inc. | Injectable formulations of ibudilast |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8562198A (en) * | 1998-08-10 | 2000-03-06 | Kyorin Pharmaceutical Co. Ltd. | Remedies for multiple sclerosis |
| WO2002045749A2 (en) | 2000-11-02 | 2002-06-13 | Research Foundation Of City University Of New York | Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
| US20050043319A1 (en) * | 2001-08-14 | 2005-02-24 | Exonhit Therapeutics Sa | Molecular target of neurotoxicity |
| AU2004292445B2 (en) | 2003-11-21 | 2010-02-04 | Zalicus Inc. | Methods and reagents for the treatment of inflammatory disorders |
| WO2006063048A2 (en) * | 2004-12-06 | 2006-06-15 | Avigen, Inc. | Ibudilast for treating neuropathic pain and associated syndromes |
| EP1940389A2 (en) * | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
-
2008
- 2008-07-08 EP EP12196108A patent/EP2567699A1/en not_active Withdrawn
- 2008-07-08 PT PT87814984T patent/PT2187882E/pt unknown
- 2008-07-08 US US12/169,042 patent/US8138201B2/en active Active
- 2008-07-08 EP EP08781498A patent/EP2187882B1/en active Active
- 2008-07-08 JP JP2010516198A patent/JP5468001B2/ja active Active
- 2008-07-08 PL PL08781498T patent/PL2187882T3/pl unknown
- 2008-07-08 ES ES08781498T patent/ES2402175T3/es active Active
- 2008-07-08 CN CN200880106623XA patent/CN101848712B/zh active Active
- 2008-07-08 WO PCT/US2008/069417 patent/WO2009009529A1/en active Application Filing
- 2008-07-08 BR BRPI0814624-1A2A patent/BRPI0814624A2/pt not_active Application Discontinuation
- 2008-07-08 CA CA2970273A patent/CA2970273C/en active Active
- 2008-07-08 AU AU2008275148A patent/AU2008275148A1/en not_active Abandoned
- 2008-07-08 DK DK08781498.4T patent/DK2187882T3/da active
- 2008-07-08 CA CA2693697A patent/CA2693697C/en active Active
- 2008-07-10 TW TW097126065A patent/TW200918051A/zh unknown
-
2012
- 2012-02-22 US US13/402,702 patent/US8338453B2/en active Active
- 2012-12-21 US US13/725,627 patent/US9114136B2/en active Active
-
2013
- 2013-01-23 HR HRP20130057AT patent/HRP20130057T1/hr unknown
- 2013-12-10 JP JP2013255214A patent/JP2014062118A/ja active Pending
-
2014
- 2014-02-24 US US14/188,061 patent/US9314452B2/en active Active
- 2014-09-19 US US14/491,939 patent/US20150011581A1/en not_active Abandoned
-
2016
- 2016-03-23 US US15/078,291 patent/US20170014390A1/en not_active Abandoned
- 2016-10-07 US US15/288,582 patent/US20170020851A1/en not_active Abandoned
-
2019
- 2019-05-01 US US16/400,844 patent/US11083713B2/en active Active
-
2021
- 2021-07-02 US US17/366,563 patent/US11944607B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2187882T3 (da) | Behandling af progressiv neurodegenerativ sygdom med ibudilast | |
| DK2222272T3 (da) | Behandling af luftvejssygdom | |
| DK2056807T3 (da) | Behandling af inflammatoriske sygdomme | |
| DK3421603T3 (da) | Genterapi for neurodegenerative forstyrrelser | |
| DK2440230T3 (da) | Behandlingsregimener til behandling af neurologisk sygdom | |
| DK3192520T3 (da) | Terapeutiske midler til reducering af niveauerne af parathyreoideahormon | |
| BRPI0811265A2 (pt) | Tratamento de sinucleinopatias | |
| BR112014010164A2 (pt) | implante de tecido duro | |
| DK2627345T3 (da) | Formuleringer til behandling af sygdomme i de øvre luftveje | |
| BRPI0813516A2 (pt) | Tratamento de distúrbios proliferativos de células b | |
| DK2111555T3 (da) | Diagnosticering af præeklampsi | |
| DK2004204T3 (da) | Behandling af neurodegenerative sygdomme med selenat | |
| BRPI0909221A2 (pt) | Desordens neurodegenerativas | |
| DK2107870T3 (da) | Lavement med reduceret irritationseffekt til behandling af inflammatorisk tarmsygdom | |
| DK3276004T3 (da) | Fremgangsmåder til behandling af kronisk nyresygdom | |
| DK2358714T3 (da) | Alkylcyclohexylethere af dihydrotetraazabenzoazulener | |
| BRPI0813670A2 (pt) | Compostos para tratamento | |
| DK2114147T3 (da) | Reduktion af bivirkninger af tramadol | |
| BRPI0820410A2 (pt) | Lactans substituídos terapêuticos | |
| DK2117565T3 (da) | Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme | |
| BRPI1011535A2 (pt) | tratamento de distúrbios resistentes à insulina. | |
| DK2501381T3 (da) | Behandling af atrieflimmer | |
| BRPI0818598A2 (pt) | agentes terapêuticos - 802 | |
| BRPI1010516A2 (pt) | Métodos de tratamento de edema relacionados à isquemia-reperfusão | |
| DK2175849T3 (da) | Behandling af melanomer |